XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full
How this was made
The 30-second read
Why it matters
Traders can update models using the tightened 2026 total revenue guidance ($385–$390 million) and the disclosed operating drivers: Recorlev net product revenue growth, improved gross margin, and the non-cash convertible-note fair value charge affecting GAAP net loss.
Market read
The filing combines a company-specific earnings/guidance update with IP and capital-structure milestones, creating actionable inputs for near-term positioning in XERS.
What to watch
Royalty, contract and other revenue fell sharply year over year, and R&D and SG&A both rose materially, which could pressure margins if growth slows later in 2H 2026.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings release for Xeris Biopharma’s second quarter ended June 30, 2026.
Ticker impact
Xeris reports Q2 results with net product revenue up 34% and tightens 2026 total revenue guidance to $385–$390 million.
Bias upward for the next few sessions as traders focus on raised/firmed revenue outlook and product momentum, with volatility around financing-related accounting items.
The filing is a primary earnings and guidance update (8-K with exhibit), includes specific revenue guidance and operating drivers, and quantifies the one-time non-cash charge tied to 2028 convertible note exchange accounting.
Market effects
Adds datapoints on commercial traction for rare-disease biopharma products and how patent milestones can reinforce long-duration revenue visibility.
Primarily impacts US small/mid-cap biotech sentiment and Nasdaq rare-disease peers via read-through on demand and IP durability.
Limited global spillover; mostly company-specific unless peers react to similar IP or commercial execution signals.
Counterpoint
The headline GAAP loss is dominated by a large one-time non-cash charge from convertible note exchange accounting, so investors should separate cash earnings power from accounting optics.
Key entities
- companyXeris Biopharma Holdings, Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and tightening full-year 2026 revenue guidance.
- productRecorlev
Xeris product whose net product revenue grew 34% year over year in Q2 2026, driving overall product revenue growth.
- productKeveyis
Xeris product receiving a USPTO Notice of Allowance for a new patent expected to extend protection through at least 2039.
- capital_structure2028 Convertible Notes
Xeris entered exchange agreements eliminating remaining 2028 convertible notes outstanding, with a related non-cash fair value charge impacting GAAP results.
